Nurix Therapeutics, Inc.

NRIX

US67080M1036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-16 pm EDT			5-day change	1st Jan Change
25.44 ^USD	+2.58%		+9.04%	+146.51%

Aug. 26	Nurix Therapeutics Insider Sold Shares Worth $504,370, According to a Recent SEC Filing	MT
Aug. 14	Oppenheimer Adjusts Nurix Therapeutics Price Target to $27 From $25	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Nurix Therapeutics, Inc.

Nurix Therapeutics Insider Sold Shares Worth $504,370, According to a Recent SEC Filing	Aug. 26	MT
Oppenheimer Adjusts Nurix Therapeutics Price Target to $27 From $25	Aug. 14	MT
Truist Securities Starts Nurix Therapeutics With Buy Rating, $36 Price Target	Jul. 31	MT
Truist Securities Initiates Nurix Therapeutics at Buy With $36 Price Target	Jul. 31	MT
Transcript : Nurix Therapeutics, Inc. Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 02:30 PM	Jul. 15
Barclays Adjusts Price Target on Nurix Therapeutics to $31 From $20, Maintains Overweight Rating	Jul. 15	MT
JPMorgan Adjusts Price Target on Nurix Therapeutics to $34 From $31, Maintains Overweight Rating	Jul. 15	MT
Needham Adjusts Price Target on Nurix Therapeutics to $29 From $31, Maintains Buy Rating	Jul. 12	MT
RBC Lifts Price Target on Nurix Therapeutics to $27 From $26, Keeps Outperform, Speculative Risk	Jul. 12	MT
Nurix Therapeutics Q2 Loss Widens Amid Revenue Decline	Jul. 11	MT
Nurix Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024	Jul. 11	CI
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q2 Revenue $12.1M	Jul. 11	MT
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell Microcap Growth Index	Jun. 30	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 3000E Growth Index	Jun. 30	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 3000 Growth Index	Jun. 30	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 2000 Growth Index	Jun. 30	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 2500 Growth Index	Jun. 30	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
RBC Raises Price Target on Nurix Therapeutics to $26 From $23, Maintains Outperform, Speculative Risk	Jun. 27	MT
Nurix Therapeutics Insider Sold Shares Worth $400,216, According to a Recent SEC Filing	Jun. 20	MT
HC Wainwright Raises Price Target on Nurix Therapeutics to $26 From $19, Maintains Buy Rating	Jun. 18	MT
JPMorgan Adjusts Price Target on Nurix Therapeutics to $31 From $30, Maintains Overweight Rating	Jun. 17	MT
Sector Update: Health Care Stocks Decline Premarket Monday	Jun. 17	MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell	Jun. 17	MT
Sector Update: Health Care	Jun. 17	MT

Chart Nurix Therapeutics, Inc.

Duration

Period

More charts

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).

Employees

284

Sector

Biotechnology & Medical Research

Calendar

2024-10-09 - Q3 2024 Earnings Release (Projected)

More about the company